Solutia Reports Third Quarter 20...(ns) 2009 ...)

Date:10/26/2009

ns) 2009 2008 ---- ---- Income (Loss) from Continuing Operations $31 $23 Net Income attributable to noncontrolling interest (2) (2) --- --- Income (Loss) from Continuing Operations attributable to Solutia 29 21 Plus: Events affecting comparability, pre-tax: Reorganization items - - Interest expense items - 1 Other items (see below) 16 (1) Events affecting comparability, income tax impact (1) - --- --- Income from Continuing Operations attributable to Solutia before events affecting comparability $44 $21 --- --- Successor Predecessor Successor Combined --------- ----------- --------- -------- Nine Months Two Months Seven Months Nine Months Ended Ended Ended Ended September 30, February 29, September 30, September 30, (dollars in millions) 2009 2008 2008 2008 ---- ---- ---- ---- Income (Loss) from Continuing Operations $52 $1,250 $4 $1,254 Net Income attributable to noncontrolling interest (3) - (5) (5)
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009